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Abstract
Streptococcus pneumoniae is a human pathogen responsible for the majority of childhood pneumonia and
media otitis cases worldwide. The diversity of its capsular polysaccharides (CPS) results in more than 91
serotypes of which at least 23 are virulent. Various CPS conjugated to immunogenic carrier proteins are
currently licensed and provide protection against the infection caused by the respective serotypes but not
against new and emerging virulent serotypes. In this study, we considered the conserved protein antigen PsaA,
the pneumococcal surface adhesin A, in order to overcome the limitations of CPS antigens. The PsaA was
translationally fused to a polyhydroxybutyrate (PHB) synthase which mediated production of PsaA displayed
on PHB inclusions in recombinant Escherichia coli. This suggested that the PsaA fusion to the PHB synthase
did not interfere with PHB synthase activity and its ability to mediate formation of nano-sized inclusions
composed of a PHB core surrounded by the PHB synthase fused to PsaA. Isolated PHB beads showed a
negative surface charge. Transmission electron microscopy analysis suggested that the PsaA fusion to the PHB
synthase reduced the size of PHB beads from about 500 nm to 100 nm. The integrity and antigenicity of the
fusion protein attached to isolated PHB beads was confirmed by SDS-PAGE, tryptic peptide fingerprinting
analysis using MALDI-TOF-MS/MS and immunoblotting using a monoclonal anti-PsaA antibody. Mice
immunized with PsaA displaying PHB beads produced high and specific IgG levels dominated by IgG1
isotype. While IgG1 titer were similar between soluble and insoluble PsaA, the IgG2 titers were strongly
increased upon vaccination with insoluble PsaA i.e. PsaA displayed on PHB beads. Particulate PsaA-PHB
beads elicited IgG antibodies recognizing PsaA in whole cell lysates of seven different serotypes of S.
pneumoniae. This study suggested that PHB beads are suitable carriers for PsaA in order to induce a
significant and specific Th-2-type immune response.
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Abstract
Streptococcus pneumoniae is a human pathogen responsible for the majority of
childhood pneumonia and media otitis cases worldwide. The diversity of its
capsular polysaccharides (CPS) results in more than 91 serotypes of which at least
23 are virulent. Various CPS conjugated to immunogenic carrier proteins are
currently licensed and provide protection against the infection caused by the
respective serotypes but not against new and emerging virulent serotypes. In this
study, we considered the conserved protein antigen PsaA, the pneumococcal
surface adhesin A, in order to overcome the limitations of CPS antigens. The PsaA
was translationally fused to a polyhydroxybutyrate (PHB) synthase which
mediated production of PsaA displayed on PHB inclusions in recombinant
Escherichia coli. This suggested that the PsaA fusion to the PHB synthase did not
interfere with PHB synthase activity and its ability to mediate formation of nano-
sized inclusions composed of a PHB core surrounded by the PHB synthase fused to
PsaA. Isolated PHB beads showed a negative surface charge. Transmission
electron microscopy analysis suggested that the PsaA fusion to the PHB synthase
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antigenicity of the fusion protein attached to isolated PHB beads was confirmed by
SDS-PAGE, tryptic peptide fingerprinting analysis using MALDI-TOF-MS/MS
and immunoblotting using a monoclonal anti-PsaA antibody. Mice immunized
with PsaA displaying PHB beads produced high and specific IgG levels dominated
by IgG1 isotype. While IgG1 titer were similar between soluble and insoluble
PsaA, the IgG2 titers were strongly increased upon vaccination with insoluble
PsaA i.e. PsaA displayed on PHB beads. Particulate PsaA-PHB beads elicited IgG
antibodies recognizing PsaA in whole cell lysates of seven different serotypes of S.
pneumoniae. This study suggested that PHB beads are suitable carriers for PsaA in
order to induce a significant and specific Th-2-type immune response.
Keywords: Immunology, Vaccines, Biochemistry, Pharmaceutical science
1. Introduction
Streptococcus pneumoniae is considered as most important pathogen causing
severe pneumonia, meningitis and middle ear inflammation [1]. The cell surface of
S. pneumoniae contains various proteins and capsular polysacharides (CPS) which
play an important role in pathogenicity such as attachment and immune system
evasion. The diversity of CPS contributes to more than 91 serotypes, while cell
surface proteins were found to be more conserved and less variable [2]. Hence, S.
pneumoniae cell surface proteins are increasingly considered as vaccine candidate
antigens.
All licensed vaccines are conjugated CPS based and induce a specific serotype
dependent protective immune response profile i.e. a strong and specific Th2-type
response [3]. However, the emergence of new invasive serotypes not covered by
existing vaccines demands attention.
Subunit vaccines based on conserved proteins/epitopes could induce serotype
independent and more broadly protective immunity [3]. Due to their relevance for
pathogenicity, cell surface proteins such as pneumococcal surface protein A
(PspA), pneumococcal surface antigen A (PsaA) and pneumolysin (Ply) are
currently being considered for vaccine development [4, 5, 6]. As subunit vaccines
are often less immunogenic, adjuvant and/or immunogenic delivery systems are
needed. Recently, polyhydroxybutyrate (PHB) beads (< 1 μm) displaying specific
antigens had been demonstrated as effective antigen delivery system in the context
of the intracellular pathogens [7, 8]. PHB is a polyester naturally produced by
various bacteria [9]. Introducing PHB biosynthesis genes into heterologous
expression hosts, allows the intracellular formation of discrete and spherical PHB
inclusions [10]. This also resulted in PHB inclusions densely coated with proteins
of interest [11, 12, 13, 14, 15, 16]. Translational fusion of proteins of interest to
PHB synthase, PhaC, retained its PHB bead forming activity displaying the protein
of interest at the PHB bead surface [13, 17]. PHB beads were bioengineered to
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display antigens from intracellular pathogens like Mycobacterium tuberculosis and
Hepatitis C virus. These particulate vaccine candidates elicited both Th1 and Th2
antigen specific immune responses resulting in protective immunity [8, 18, 19]. In
this study it was conceived to engineer PHB beads displaying PsaA as possible
antigen delivery system to develop a particulate vaccine against the extracellular
pathogen S. pneumoniae.
2. Materials and methods
2.1. Bacterial strains, oligonucleotides, plasmids and cultivation
condition
Bacterial strains, plasmids and primers used in this study are listed in Table 1. E.
coli XL 1 blue was grown at 37 °C in Luria Bertani (LB) in presence of ampicillin
(100 μg/mL). PHB beads and recombinant soluble protein was produced in
recombinant ClearColi [20]. ClearColi was grown in LB Miller media
supplemented with glucose 1% (w/v), ampicillin (100 μg/mL). Chloramphenicol
(50 μg/mL) was only added to media used for PHB bead production.
2.2. Construction of plasmids mediating production of PHB
beads displaying PsaA
The gene encoding PsaA (amino acids 22–309) was synthetized by Genscript
Corporation (USA) employing codon optimization for E. coli [24]. This hybrid
gene encoding a translational fusion of PsaA with PhaC was constructed and
cloned into plasmid pET-14b as outlined in Fig. 1.
2.3. Construction of the plasmid encoding N-terminally His-
tagged PsaA for production of soluble PsaA
The gene encoding PsaA was amplified from pUC57-psaA by PCR using the
corresponding primers psaA-fwr and psaA-rev. This introduced 6 histidine residues
into the N terminus of PsaA in order to enable purification by immobilized Ni2+
affinity chromatography. The gene encoding His6-PsaA was inserted into pET-
14b_NanA_PhaC using hydrolysis with NdeI and BamHI to replace nanA.
2.4. Production, isolation and purification of PHB beads
ClearColi harboring pMCS69 was transformed with pET-14b-psaA-phaC (encod-
ing PsaA-PhaC fusion protein for production of PsaA displaying PHB beads) and
pET14b-PhaC (PhaC wildtype control for production of PHB beads). Cells were
cultivated and subjected to mechanical cell disruption. Beads were isolated and
sterilized as previously described [25, 26].
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Table 1. Description of bacterial strains, plasmids and oligonucleotides used in this study.
Strains, plasmid and primers Characteristics Review
Strains
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB lacIqZΔM15 Tn10 (Tetr)] Stratagene




pET-14b ApR and T7 promoter Novagen
pET-14b-phaC pET-14b version, holding phaC gene fragment [21]
pUC57-psaA pUC57 version, ColE1 origin, ApR holding NdeI/psaA gene/SpeI. GenScript
pET-14b-psaA-phaC pET-14b-phaC version, holding psaA gene fused to 3′ end of phaC gene This study
pMCS69 CmR; T7 promoter, pBBR1MCS derivative containing phaA and phaB genes from Ralstonia eutropha co-downstream to lac promoter [22]
pET14b_NanA_PhaC (reversed) ApR and T7 promoter, containing nanA gene cloned to 3′ end of phaC gene [23]
pET14b- his6-psaA ApR and T7 promoter, containing the his6-psaA gene inserted into the NdeI//BamHI sites of pET14b. This study
Primers
psaA fwr (NdeI, underline restriction
site)
5′AAACATATGCACCACCACCACCACCACTCGGGCAAAAAGGATACGACCTCGG3′ This study
psaA rev (BamHI, underline restric-
tion site)






































2.5. Production, isolation and purification of recombinant
soluble protein
ClearColi was transformed with pET-14b-his6-psaA (encoding His6-PsaA). Cells
were cultivated and lysed for purification of His6-PsaA using the Ni-NTA Fast
Start Kit (Qiagen, Germany).
2.6. Confirmation of the PhaC in vivo activity using transmission
electron microscopy (TEM)
Cells harboring plasmid pET-14b-psaA-phaC and pET-14b-phaC, respectively,
were analysed by TEM as described previously [20] to demonstrate the presence of
PHB inclusions inside cells which is indicative of in vivo functionality of PhaC and
its fusion protein variants.
2.7. Protein analysis
PsaA-PhaC and PhaC beads as well as soluble His6-PsaA were analysed by SDS-
PAGE as previously described [27]. Immunoblot analysis was conducted as
perviously described [28]. A monoclonal anti-PsaA antibody (Steroid &
Immunobiochemistry Laboratory, Canterbury Health Laboratories, Christchurch,
New Zealand) was used to identify the PsaA. All images were obteined using the
GEL-DOC 2000 (Bio-Rad Laboratories, USA) and analysed using Image Lab
Software (Version 3.0 build 11, Bio-Rad Laboratories, USA). Proteins were further
identified by MALDI-TOF/MS. To confirm the PHB bead surface display and
identity of PsaA, ELISA using goat anti-mouse IgG peroxidase conjugate (Sigma-
Aldrich, St. Louis, MO) as secondary antibody as well as CLSM (confocal laser
[(Fig._1)TD$FIG]
Fig. 1. Schematic presentation of the construction of plasmid pET-14b-psaA-phaC encoding the PsaA-
PhaC fusion protein for formation of PHB beads in recombinant ClearColi.
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scanning microscopy) using a fluorescently (Alexa fluor 488) labelled goat anti-
mouse antibody (Sigma-Aldrich, St. Louis, MO) as secondary antobody were
employed as previously described [29].
2.8. Mesurement of the PHA bead size distribution and zeta
potential
Size distribution of the particles and the zeta potential were mesured using the
Mastersizer 3000 particle sizer (Malven instrument, United Kingdon) and the
Zetasizer Nano ZS (Malven instrument, United Kingdon), respectively. Samples
were prepared as 0.1% (w/v) of the wet PHB beads in saline solution. The pH
values were adjusted with HCl.
2.9. Analysis of immunological properties of PHB beads
2.9.1. Immunization schedule
Four groups were prepared containing each 6 animals between 5–6 weeks old
(male, Balb/c mice). Mice were acquired from CENPALAB (Centro Nacional para
la Producción de Animales de Laboratorio, La Habana, Cuba). Three doses of 4 μg
of antigen plus 100 μg of alum salt (ALHYDROGEL, Brenntang Biosector,
Denmark) were subcutaneously administrated to each animal. Animals of the
placebo group received only alum salt. Immunizations occurred at 0, 14 and 21 d.
Blood samples were collected from the retro-orbital plexus at days 0, 14, 21 and 28
d after vaccination. Group 1 (G1) received 4 μg of PsaA displayed on PHBs, Group
2 (G2) received 4 μg of His6-PsaA antigen as pure soluble protein, Group 3 (G3)
received 4 μg of PhaC wild type PHB beads. Group 4 received only alum salts.
2.9.2. Assessment of anti-PsaA antibody titers in mice
Anti-PsaA and anti-PhaC IgG levels were measured using an indirect ELISA.
Maxisorp 96-well plates (NUNC) were coated using 0.5 μg/ml of His6-PsaA and
incubation overnight at 4 °C. The plates were then washed with PBS containing
0.05% (v/v) Tween 20 (PBS-T) and blocked for 30 min at 37 °C with PBS
containing 1% (w/v) BSA. After three washes with PBS-T, plates were incubated
with dilutions of serum samples from individual mice in PBS-T containing 1% (w/
v) BSA and 12.6 mM of EDTA (PBS-TB), for 60 min at room temperature (RT).
The initial dilution factor (DF) of all samples was 1600. After three washes with
PBS-T, plates were incubated for 60 min with the secondary antibody, the goat
anti-mouse IgG peroxidase conjugate (Sigma-Aldrich, St. Louis, MO) diluted
1:10,000 in PBS-TB. Plates were developed using the peroxidase substrate as
described elsewhere [30]. A serum was considered as positive if the initial
absorbance at a wavelength of 570 nm was equal or greater twofold of the pre-
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immune serum value. Results were displayed as the reciprocal antibody titres,
representing the DF required to obtain half of the maximum level of absorbance.
2.9.3. Analysis of the isotype IgG profile in sera
The isotype IgG profile against PsaA was analysed by using an indirect ELISA as
described above. Pools of sera from all animals at time 28 d from G1 and G2 were
prepared and diluted 1:1600. To detect the various IgG isotypes, plates were
incubated with the respective anti-IgG1, IgG2a, IgG2b and IgG3 antibodies
(derived from goat) (Sigma-Aldrich, St. Louis, MO) using a DF of 1:2500. Plates
were developed using the anti-goat IgG peroxidase conjugate and the respective
substrate as described above. The results from duplicate experiments are
represented as mean values plus standard deviation (Mean ± STD).
2.9.4. Serotype coverage of induced anti-PsaA antibodies
The specificity of sera from animals immunized with PsaA-PhaC PHB beads for
PsaA in whole cell lysates of pathogenic S. pneumoniae serotypes 1, 3, 5, 6b, 7F,
14 and 23F was assessed by immunoblotting. Cell suspension were prepared in
PBS (pH 7.0) and adjusted to an OD620 0.8–1. Then 300 μl of these suspensions
were mixed with denaturing buffer (DF 2). Samples were incubated at 95 °C for 20
min. Twenty μl of soluble sample were separated by SDS-PAGE. For
immunoblotting pooled sera from all animals of G1 (DF: 2000) and G2 (DF:
500) were used to assess whether induced antibodies would detect PsaA in various
S. pneumoniae serotypes.
2.10. Statistical analyses
Graph Pad Prism 4.03 (San Diego, USA) software was used for statistical analysis
of data. Results were reported as results of 6 animals and significant differences
were calculated by the Kruskal–Wallis non-parametric test. When significant
differences were found, the Dunn’s post-test was used, considering significant
differences when P was less than 0.05.
3. Results
3.1. Construction of plasmids mediating production of the PsaA-
PhaC fusion protein and His6-PsaA
The strategy for construction of plasmids encoding PsaA from S. pneumoniae
translationally fused to PhaC from Ralstonia eutropha for production of particulate
PsaA is presented in Fig. 1.
In this study, the amino acid sequence of PsaA, the manganese ABC transporter, a
manganese-binding adhesion lipoprotein, was selected from S. pneumoniae
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CGSP14 (GenBank number: ACB90875.1). This sequence has 100% identity with
orthologous proteins found in strains R6 and TIGR4, and 98–99% identity with the
other orthologues of various S. pneumoniae strains deposited in NCBI database.
The gene encoding PsaA without its predicted signal sequence (1–21 amino acid
residues) was synthetized as codon–optimized for E. coli (GenScript, USA). This
synthetic gene was used to construct pET-14b-psaA-phaC. The recombinant
soluble version of PsaA was produced as N-terminally His6-tagged protein and
purified Ni2+ affinity chromatography.
3.2. Production and characterization of PsaA displaying PHA
beads
To produce PHB beads, ClearColi harbouring pMCS69 (Table 1) were
transformed with either pET-14b-psaA-phaC or pET-14b-phaC (non-antigen
displaying negative control). To confirm the formation of PHB inclusions
indicative of PhaC functionality, cells and purified beads were observed by
TEM (Fig. 2). Results showed that both plasmids mediated formation of distinct
inclusions. However, PHB inclusions which formation was mediated by the PsaA-
PhaC were smaller and more abundant when compared to inclusions formed by
only PhaC (Fig. 2).
[(Fig._2)TD$FIG]
Fig. 2. TEM analysis of recombinant Clearcoli cells (pMCS69) harboring various plasmids and
respective isolated PHB beads. A, cells harboring pET-14b-phaC (PhaC wildtype PHB beads); B, cells
harboring pET-14b-psaA-phaC (PsaA-PhaC PHB beads); C, PHB beads isolated from cells harboring
pET-14b-phaC; D, PHB beads isolated from cells harboring pET-14b-psaA-phaC.
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After isolation and purification, the protein profile of PHB beads and His6-PsaA
was analysed by SDS-PAGE and immunoblotting (Fig. 3).
In Fig. 3A dominating protein bands are observed which correspond to the
theoretical molecular weights of the various proteins of interest such as His6-PsaA
(34 kDa) (soluble antigen control, PhaC (MW: 66 kDa) (mediating non-antigen
displaying PHB bead formation) and PsaA-PhaC fusion protein (MW: 97 kDa)
(mediating PsaA displaying PHB bead formation). The identity of proteins was
further confirmed by immunoblotting using a specific anti-PsaA antibody (Fig. 3B)
and by tryptic peptide fingerprinting analysis using Maldi-TOF/MS (Table 2).
The SDS-PAGE analysis also showed a strong enrichment of the target proteins
while the immunoblot confirmed identity and stability of the target protein with no
obvious proteolytic truncation (Fig. 3). Densitometry suggested a purity of ≥95%.
[(Fig._3)TD$FIG]
Fig. 3. SDS-PAGE and immunoblot analysis of proteins attached to PHB beads and purified His6-
PsaA. A, Comassie blue stained SDS-PAGE gel; B, immunoblot of (A) developed using monoclonal
anti-PsaA antibodies. Lane 1, Molecular weight (MW) standard (Novex® Sharp Pre-Stained Protein
Standard, Invitrogen); lane 2, purified His6-PsaA (MW: 34 kDa) derived from cells harboring pET14b-
his6-psaA; lane 3, PHB beads isolated from cells harboring pET-14b-phaC encoding PhaC (MW: 64.5
kDa); lane 4, PHB beads isolated from cells harboring pET-14b-psaA-phaC encoding PsaA-PhaC
fusion protein (MW: 97 kDa). The arrows indicate the protein band of interest with the corresponding
theoretical MW.
Table 2. Tryptic peptide fingerprinting analysis (MALDI-TOF/MS).
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In order to determine whether PsaA is displayed on the surface of the PHB beads,
an ELISA and CLSM was employed which showed binding of the anti-PsaA
antibody to the surface of PHB beads which formation was mediated by the PsaA-
PhaC fusion protein (Fig. 4)
To determine the amount of PsaA- PhaC fusion protein attached to PHB beads,
SDS-PAGE analysis including defined amount of BSA for generation of a
densitometry based standard curve was applied. Densitometry using Image
Analysis Software served to deduce the amount of protein per amount of PHB
bead. The amount of PsaA-PhaC or PhaC per PHB bead is shown in Table 3. These
data were used to calculate the amount of PHB beads to be injected per dose.
[(Fig._4)TD$FIG]
Fig. 4. Immunological assessment of PsaA display on the PHB bead surface. The specific monoclonal
anti-PsaA antibody (see Materials and Methods) was used to detect PsaA at the surface of PHB beads
by ELISA (A) and CLSM (B and C). A, Plates were coated with PsaA-PhaC beads, PhaC beads and
soluble His6-PsaA. Anti-IgG HRP-conjugated secondary antibody was used to detect the bound primary
anti-PsaA antibody. Data showed that the anti-PsaA antibody bound to PsaA on PHB beads as well as
soluble PsaA while PhaC bead (negative control) did not show any binding. Each data point represented
the mean of two replicates plus standard deviation. CLSM was further used to demonstrated PsaA
surface display by detecting bound anti-PsaA antibodies with a secondary fluorescently labelled (Alexa
fluor 488) antibody. PhaC beads (B) and PsaA-PhaC beads (C) were, after incubation with primary and
seconday antibody, observed by CLSM. Fluorescent label of beads in the middle column (B, C) is
indicative of PsaA display. DIC, differential interference contrast.
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The Zeta potential of PHB beads was measured as a function of the pH (pH 3–7.5)
suggesting a negative surface charge for both PHB beads (Fig. 5). However,
display of PsaA further increased the negative surface charge.
3.3. Humoral immune response
During the immunization schedule all animals remained healthy and alive; they
were gaining weight and showed no abnormal behaviour (data not shown). In the
groups (G1 and G3) immunized with PsaA-PhaC and PhaC PHB beads small
granulomas were detected (about 2 mm) at injection sites but no suppuration was
observed. After euthanasia, the liver, lung, spleen and kidneys of the animals from
groups G1, G2 and G3 showed no differences when compared with organs of
animals which received the Placebo (G4).
[(Fig._5)TD$FIG]
Fig. 5. Correlation between zeta potential and pH of various PHB beads. Error bar represent the mean
plus standard deviation between three measurements.
Table 3. PHB bead yield and composition.












pET-14b-psaA-phaC 4 32.8 1.63 34 0.39
pET-14b-phaC 4 29.4 5.51 0 1
Article No~e00291
11 http://dx.doi.org/10.1016/j.heliyon.2017.e00291
2405-8440/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
IgG titers specific towards PsaA after each immunization dose are shown in Fig. 6.
The absorbance value obtained in G1 and G2 showed induction of specific anti-
PsaA antibodies when compared with control groups G3 and G4. Besides, the
tendency of an increase in IgG titer after each dose was evident and significant for
G1 and G2 (first dose vs third dose with (p < 0.001)). As expected the highest
titers for these groups were achieved after the third dose presenting significant
differences in comparison with G3 and G4 ((p < 0.01 and (p < 0.05)),
respectively. No statistical significant differences were found between G1 and G2.
The humoral response was further studied, evaluating the IgG subclass profile in
sera of animals 7 d after the last immunization. This analysis included subclasses
IgG1, IgG2a, IgG2b and IgG3. IgG1 was the prevalent isotype elicited in G1 and
G2. Interesting in the group immunized with PsaA-PhaC fusion protein on PHB
beads IgG2b was the second prevalent subtype showing higher titers than the other
isotypes (Fig. 7).
To assess whether induced anti-PsaA antibodies would recognize PsaA in whole
cell lysates from different serotypes of S. pneumoniae, an immunoblot was
performed using pooled sera from G1 and G2 obtained 7 d after the last
[(Fig._6)TD$FIG]
Fig. 6. Anti-PsaA IgG antibody response. Anti-PsaA IgG antibody titers were obtained by ELISA. G1
(grey diamond) group immunized with 4 μg of PsaA fused to PhaC and displayed on PHA beads, G2
(black circle) group immunized with 4 μg of His6-PsaA, G3 (black triangle) group immunized with 4 μg
of PhaC wild type bead (no antigen PHB bead negative control) and G4 (black square) (placebo) group
immunized with only 100 μg Alum salt. All of the immunogens were extracted from E. coli (Clearcoli,
LPS free E. coli strain). Data are shown as reciprocal antibody titres, representing the dilution required
to obtain half of the maximal OD value at 450/570 nm. a,bStatistical significant difference (p < 0.001).
cSignificantly greater than the third dose of placebo and PhaC immunized control group (p < 0.01),
dSignificantly greater than the third dose of placebo and PhaC immunized control group (p < 0.05). No
statistical differences were found after third dose between G1 and G2 (p = 0.240).
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immunization (Fig. 8). Antibodies in sera of both groups G1 and G2 were
predominantly detecting a protein with an apparent molecular weight of 37 kDa
which corresponds with the theoretical molecular weight of PsaA and aligned with
the purified PsaA. Insterestingly, to get a visible band the sera from G2 had to be 4-
fold more concentrated than from G1 suggesting enhanced production of the
antibodies elicited after immunization with PsaA displayed on PHB beads versus
its soluble counterpart.
4. Discussion
Current vaccines against S. pneumoniae infections are limited to protect against
certain serotypes excluding important invasive pathogenic serotypes. Hence a
serotype independent broadly protective vaccine, such as a vaccine based on
conserved cell surface proteins could provide an alternative approach toward
vaccine development.
PsaA has been considered as one of the most important vaccine candidate antigens
as it plays a critical role during pathogenesis and is conserved among virulent
strains. It induces both B-cell and T-cell responses. In this study we evaluated the
concept of improving delivery and immunogenicity of PsaA by its display on PHB
inclusions. Antigen displaying PHB beads (<1 μm) had been produced by
engineered E. coli and induced both Th1 and Th2 immune responses as well as
[(Fig._7)TD$FIG]
Fig. 7. Isotype IgG profile evaluated by direct ELISA using ELISA plates coated with 0.5 μg of soluble
His6-PsaA. The results are expressed as the average plus STD of absorbance readings at 450/570 nm
using pooled of sera (6 animals) from G1 and G2. The sera were collected 1 week after third dose. The
STD bars are only indicated in plus direction. G1 (grey bars) group immunized with 4 μg of PsaA
displayed on PHB beads, G2 (black point bars) group immunized with 4 μg of soluble His6-PsaA. IgG1
is the prevalent isotype in both groups.
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mediated protective immunity against tuberculosis and hepatitis C [8, 18, 31].
Antigen PHB beads are presumable taken up by phagocytosis of antigen presenting
cells (APCs) which creates an antigen depot and allows cross presentation on MHC
class I and class II, which would further enhance PsaA immunogenicity [8, 29, 31].
In addition, it was shown that the co-administration of Th1-promoting adjuvants to
protein-based S. pneumoniae vaccine candidates induced protective immunity [32].
This suggested that the Th1 immune response might contribute to protective
immunity against the extracellular pathogen S. pneumoniae. This did further justify
considering particulate vaccine such as PHB beads, known to induce Th1
responses, for formulation of a S. pneumoniae vaccine.
To produce PsaA displaying PHB beads, a hybrid gene was constructed (Fig. 1)
which encoded a single chain fusion protein of PsaA and the PHB forming enzyme,
[(Fig._8)TD$FIG]
Fig. 8. Recognition of PsaA in various serotypes of S. pneumoniae by sera from mice immunized with
PsaA displayed on PHB beads or soluble PsaA. A, immunoblots using sera (diluted 1:2000) from mice
immunized with PHB beads displaying PsaA (G1). The corresponding SDS-PAGE of whole cell lysates
of various S. pneumoniae serotypes is provided in Supplemental material (Fig. S1). B, immunoblot
using sera (diluted 1:500) from mice immunized with soluble PsaA (G2). Lanes, 1, 2, 3, 5, 6, 7 and 8
correspond to cell lysates from S. pneumoniae serotypes: 1, 3, 5, 6b, 7F, 14, 23F, respectively; lane 4,
MW standard and lane 9 soluble purified PsaA. The grey arrows indicate the protein corresponding to
the molecular weight expected for PsaA.
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PhaC. The fusion protein mediated production of PHB inclusions in the ClearColi,
an endotoxin-free mutant of E. coli [33] (Fig. 2). Interestingly, the fusion of PsaA
to PhaC resulted in formation of smaller PHB beads (<200 nm) than observed with
only PhaC suggesting an impact of PsaA on self-assembly of PHB beads inside the
cell (Fig. 2). Protein and immunoblot analysis confirmed that PHB beads displayed
the full-length PsaA at high-copy number with only minor indication of
degradation (Figs. 3 and 4, Table 2). PHB beads as antigen carrier isolated from
recombinant E. coli were recently demonstrated to induce only antigen specific
responses, while potentially co-purifying E. coli proteins did not induce a
detectable responses [19]. As the surface charge of particulate vaccine might
impact cellular uptake and antigen processing, we assessed the Zeta potential of
isolated PHB beads which resulted in anegative charge at physiological pH with an
increased negative Zeta potential for the PsaA-PHB beads (Fig. 5). Particulate
vaccine formulations which are designed for improved uptake of antigens by APCs
are known to activate the NLRP3 inflammasome,which enhances efficacy of the
vaccine [34]. Activation of the NLRP3 inflammasome was found to dependent on
the surface charge of the vaccine particle.
To compare immunological properties of soluble and particulate PsaA, the soluble
PsaA was produced in ClearColi and purified by affinity chromatography to ≥95%
purity (Fig. 3). Vaccination experiments showed that IgG levels elicited by PsaA
on PHB beads were significantly greater than those induced by PHB beads and
within the placebo group (p < 0.01 and p < 0.05, respectively). Antibodies against
bacterial antigens like cell surface proteins (e.g. PsaA or PspA) were shown to
interfere with binding and internalization by the mucosal-nasopharyngeal cells,
impairing entrance of the pathogen into blood circulation [35, 36]. In particular, the
results obtained by De et al. [37] after immunization with PsaA, reinforces the
above stated. In vitro studies further demonstrated that anti-PsaA antibodies
inhibited adherence of various S. pneumoniae serotypes to nasopharyngeal human
carcinoma cells [38]. PsaA trapped in alginate microspheres was demonstrated to
mediate reduction of S. pneumoniae colonization resulting in protection against
pneumonia and septicaemia [39].
Production of human IgG1 was related to clearance of extracellular pathogens by
activating phagocytosis of pathogens by macrophages (and other phagocytic cells)
through Fc receptor antibody interaction. Here immunization with PsaA displaying
PHB beads induced predominantly IgG1 (Figs. 6 and 7). This result agrees with the
study presented by Palmiappan et al., [40] where oral immunization with a S.
pneumoniae strain EF3030 promoted significant PsaA-specific titers of subclasses
IgG1 and IgG2a [40]. However, PsaA displayed on PHB beads induced IgG2b as
the second predominant IgG subclass (Fig. 7). These subclasses (IgG2a/b) of
antibodies are generally identified as part of a Th1 immune response usually
associated with an immune response to intracellular pathogens. However, studies
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on a murine pneumococcal carrier model illustrated the induction of IgG2b and
IgG3 to be important against S. pneumoniae strain P1121 infection [41].
Due to their more conserved nature protein-based vaccines are potentially more
broadly protective against various sertotypes of S. pneumoniae as they induce a
serotype independent immune response. To assess whether PsaA on PHB beads
induced production of cross-reactive antibodies, we tested reactivity of whole cell
proteins of serotypes 1, 3, 5, 6b, 7F, 14, 23F with antibodies in pooled sera of
vaccinated mice (Fig. 8). These data clearly suggested that serotype independent
anti-PsaA antibodies were induced by PsaA displaying PHB beads and by soluble
PsaA. However, anti-PsaA antibody titers in response to PsaA displaying PHB
were greater than antibody titers induced by soluble PsaA. Our results agree with
previous studies where PsaA was suggested to be conserved among serotypes
suitable for use as antigen for broadly protective vaccines [42, 43, 44]. The PsaA
displayed in the surface of PHB beads was selected from the strain CGSP14 which
PsaA is identical to PsaA of strains R6 and TIGR4 (Serotype 14) and shows
98–99% amino acid sequence identity with all other deposited PsaA protein
sequences in the current NCBI database [24, 45]. Overall, this study demonstrated
that bioengineering can be used to produce immunogenic PsaA displaying PHB
beads, which mediate a serotype independent PsaA specific antibody response.
Hence the PHB bead based particulate vaccine approach holds the promise to be
applicable not only for protection against intracellular pathogens but also
extracellular pathogens such as S. pneumoniae.
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